This segment explores how treatment decisions for EGFR-mutant non-small cell lung cancer (NSCLC) are increasingly individualized despite the availability of combination frontline therapies.
This introductory segment provides an overview of the evolving treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC) and establishes the key themes for the discussion.
Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).
February 2nd 2017
